Topical ambroxol for the treatment of neuropathic pain by unknown
Background and problem
Neuropathic pain is common and difficult 
to treat. However, topical treatments such 
as transient functional desensitization of 
TRPV1 receptors as well as C-fibres with 
capsaicin 8 % and blockade of neuronal 
signal transmission with lidocaine 5 % are 
often inadequate. Other potent inhibitors 
of cutaneous nociceptors with few side ef-
fects would be welcome as topical thera-
peutic options.
Ambroxol has been authorized for the 
treatment of respiratory disorders since 
1979 and can now be freely purchased 
over the counter. Since its local anaesthet-
ic properties were recognized at an ear-
ly stage [23], ambroxol-containing pas-
tilles have also been authorized for the 
treatment of sore throat [10]. Howev-
er, the substance has never been used to 
date as an analgesic, although pain-related 
behaviours have been suppressed in an-
imal studies, even in chronic pain situa-
tions [14, 16, 27, 32]. Compared with local 
anaesthetics, ambroxol is, interestingly, a 
very potent blocker of voltage-dependent 
sodium channels, blocking these channels 
about 40 times more strongly than lido-
caine [47]. Moreover, the sodium chan-
nel subtype Nav 1.8, which is preferential-
ly expressed in nociceptive C-fibre neu-
rons [2, 6, 35, 52], is blocked more po-
tently compared to the other channel sub-
types. Since the toxicity of the substanc-
es is comparatively very low [51, 53], the 
use of an ambroxol-containing semisol-
id, topical dosage form may represent an 
interesting approach to the treatment of 
what are otherwise difficult to treat pain 
conditions.
We report below on a clinically rele-
vant analgesia produced by topical am-
broxol in neuropathic pain.
Method
By way of example, we present the case 
histories of seven patients with neuro-
pathic pain that was resistant to other/
standard treatment and who benefitted 
from topical ambroxol. Within the set-
ting of an outpatient pain clinic they were 
treated in a peripheral, defined part of 
the body after numerous other therapeu-
tic attempts with authorized substances 
had proved unsuccessful or impossible. 
The preparation used was a 20 % cream 
(ambroxol cream 20 %, 50.0 g: ambroxol 
10.0 g, dimethyl sulfoxide 5.0 g, made up 
to 50.0 g with Linola cream), which was 
prepared pharmaceutically for each in-
dividual patient. In tests this formulation 
was shown to possess the highest concen-
tration of still soluble ambroxol.
While test treatments were adminis-
tered during the consultation, in the ma-
jority of cases the observations reported 
here were collected by the patients after 
they themselves had applied the prepara-
tion to the painful area over a prolonged 
period at home. Clinical observations and 
reports were documented in the medical 
records and retrospectively served as the 
basis for the case reports.
All the patients gave their written in-
formed consent both to the individual 
test treatment with ambroxol-containing 
creams (which were prepared individually 
and are not available as proprietary prep-
arations) and also to the use of the anon-
ymized reports, findings and possible im-
ages/videos. The observations presented 
here by way of example refer to a period of 
4 years overall and were documented and 
reported on the basis of the German pro-
fessional code of conduct for doctors (par-
ticularly §15) and the requirements of the 
Declaration of Helsinki (§37). The treat-
ments were prescribed outside the health 
insurance reimbursement scheme.
Results
We report the clinical observations col-
lected for seven patients, two women and 
five men. The causes of their neuropath-
ic pain were as follows: postherpetic neu-
ralgia (2 ×), mononeuropathy multiplex 
(1 ×), postoperative neuralgia (1 ×), deaf-
ferentation pain (1 ×), phantom pain (1 ×) 
and foot neuropathy of unknown ori-
gin (1 ×). The average pain intensity re-
ported by the patients was between 4/10 
and 6/10 (NRS), while the maximum 
pain intensity was between 6/10 and 10/10 
(NRS). The pain reduction achieved was 
between 2 and 8 points (NRS). The pa-
tients observed a reduction in pain within 
5–30 min, which lasted for between 3 and 
> 8 h (. Tab. 1). Five patients additional-
ly suffered from pain attacks, and these 
were reduced in all cases. Four of the sev-
en patients noticed clear functional im-
provements (physical activity, increased 
mobility, improved sleep, ability to work, 
etc.). None of the patients reported side 
effects or, more particularly, skin changes. 
None of the patients had been receiving 
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this treatment as their sole medication, 
and all continued taking primary medi-
cation, with occasionally varying dosages, 
over what was a prolonged treatment pe-
riod in some cases. The patient with the 
longest treatment period has been using 
topical ambroxol for 48 months (patient 
1), while the shortest case report (patient 
4) covers a period of 9 months (. Table 2).
Allodynia
Dynamic allodynia was present in six of 
the seven patients and a hyperalgesia in 
response to pinprick stimuli in four pa-
tients. Both forms were present in four 
cases, while one patient suffered from nei-
ther. Dynamic allodynia on its own was 
observed in two cases, and no patient was 
sensitive exclusively to pinprick stimu-
li (. Table 1). Irrespective of these con-
figurations, all patients were sensitive to 
ambroxol.
Pretreatment with lidocaine 5 %
Six of the seven patients had previously 
used lidocaine plasters, which proved in-
effective in four cases and helpful in two 
patients, one of whom was unable to toler-
ate them. Both of the patients experienc-
ing pain relief also reported this with am-
broxol. By contrast however, all four pa-
tients in whom the lidocaine had proved 
ineffective profited additionally from the 
effect of ambroxol.
Pretreatment with capsaicin 8 %
Three of the seven patients had also re-
ceived capsaicin 8 % as topical treatment. 
In two patients this was helpful, and one 
continues to use the medication. Both pa-
tients whose pain was relieved by capsa-
icin 8 % also experienced this relief with 
ambroxol. By contrast however, the pa-
tient in whom the capsaicin had proved 
ineffective benefitted from topical am-
broxol.
Case reports
Case report 1 (Neuropathic 
forefoot pain)
Born in 1942, this man presented in Oc-
tober 2010 (clinically) with neuropath-
ic pain in both feet. He felt as if he was 
running on coals, while his right foot felt 
as if it were gripped in a vice. Walking or 
gardening was almost impossible. The 
foot pain could not be explained in or-
thopaedic terms, either on the basis of ra-
diographs or as a result of a spondylode-
sis of L4/5 in 2007, and no polyneuropa-
thy was detected on neurographic inves-
tigation. The problem was thought to be 
‘likely of vertebral origin’. Clinical exami-
nation showed pronounced dynamic allo-
dynia and hyperalgesia in response to pin-
prick stimuli in the arch of the right foot, 
and to a lesser extent in the left foot. Gab-
apentin had been prescribed up to a dos-
age of 3 × 600 mg, supplemented by bu-
prenorphine 20 µg/h, and no further dose 
increase were possible in either case. Top-
ical lidocaine 5 % plasters had not proved 
helpful.
The first test treatment with topical 
ambroxol was started in June 2011, with 
a very successful outcome: within 5 min 
the stabbing pain, with an initial intensity 
of 8/10 on the NRS scale during the heel-
to-toe roll of the right foot, and the touch 
sensitivity of the forefoot disappeared 
completely for over 8 h. The intermittent 
treatment with topical ambroxol has been 
continued to date successfully (. Fig. 1). 
The pain has also meanwhile been treat-
ed successfully on 11 occasions with capsa-
icin 8 % plasters, and the patient now uses 
ambroxol cream in phases when the pain 
Table 1 Diagnoses and pain characteristics of treated patients
Case Diagnosis of neuropathic pain Duration of 
pain (months)
NRS Allodynia Effects of topical application
Nr. Mean Max Dynamic Pin-prick Lidocaine 5 % Capsaicin 8 %
1 Neuropathic forefoot pain 55 5 8 Yes Yes No Yes
2 Cold phantom pain 68 6 8 Yes No No n.t.
3 Neuropathic pain after total knee 
replacement
49 6 10 Yes Yes No Yes
4 Deafferentation pain 174 4 8 Yes Yes No n.t.
5 Thoracic postherpetic neuralgia 78 4 6 Yes No Yes No
6 Mononeuropathy multiplex 108 4 8 No No No n.t.
7 Trigeminal postherpetic neuralgia 6 5 8 Yes Yes Yes n.t.
NRS numerical rating scale, n.t. not tested
Table 2 Pain relief by topical ambroxol. Time of usage, functional improvement and adverse 
drug reactions (ADR)
Fall Diagnosis Ambroxol applied 
since (months)
Relief of ADR
1 Neuropathic forefoot pain 43 Walking, gardening No
2 Cold phantom pain 10 Sleep No
3 Neuropathic pain after total knee 
replacement
7 Movement No
4 Deafferentation pain 4 Continuing work No
5 Thoracic postherpetic neuralgia 32 Sleep No
6 Mononeuropathy multiplex 12 Watching TV, sleep No
7 Trigeminal postherpetic neuralgia 5 Sleep No
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recurs and the capsaicin effect is wearing 
off prior to the next application. He now 
takes gabapentin only in the evening at 
a dosage of 300 mg, while the opiate has 
been discontinued. Walking and garden-
ing are now possible again. No skin reac-
tions or other side effects have occurred 
during the treatment that has proved ef-
fective till now, without any changes, for 
4 years. This case report has been docu-
mented repeatedly on video.
Case report 2 (Cold phantom pain)
This patient presented with unusual pains: 
he complained of extremely painful cold 
sensations in both previously amputat-
ed phantom feet. A below-knee amputa-
tion of the left leg had been required for 
pAOD and diabetes mellitus in 2008, fol-
lowed by the right leg in 2009. The cold 
pains, with an intensity of NRS 7–9/10, oc-
curred sporadically several times a week, 
lasted from a few minutes to many hours 
and frequently woke the patient at night. 
He described the cold sensation as shift-
ing between the toes and balls of the feet 
and said that heat applied to the stump 
was of limited benefit. The cold phantom 
pain could be triggered by a cold environ-
ment, but also by visually perceived cold 
(e.g. images of snow). He had not experi-
enced the cold sensation prior to ampu-
tation (in terms of preamputation recall), 
and the stump itself was usually warm. 
Both stumps showed slightly increased 
cold perception on the distal lateral sides, 
on the right with additional dynamic al-
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Abstract
Background. Neuropathic pain is difficult 
to treat, and the available options are of-
ten inadequate. The expectorant ambrox-
ol also acts as a strong local anaesthetic and 
blocks sodium channels about 40 times more 
potently than lidocaine. It preferentially in-
hibits the channel subtype Nav 1.8, which 
is expressed especially in nociceptive C-fi-
bres. In view of the low toxicity of ambrox-
ol, it seemed reasonable to try using it for the 
treatment of neuropathic pain that failed to 
respond to other standard options.
Material and methods. The medical records 
of seven patients with severe neuropath-
ic pain and pain reduction following topical 
ambroxol treatment are reported retrospec-
tively. As standard therapies had not proved 
sufficient, a topical ambroxol 20 % cream was 
repeatedly applied by the patients in the area 
of neuropathic pain.
Results. The reasons for neuropathic pain 
were postherpetic neuralgia (2 ×), mononeu-
ropathy multiplex, phantom pain, deaffer-
entation pain, postoperative neuralgia and 
foot neuropathy of unknown origin. The indi-
vidual mean pain intensity reported was be-
tween 4 and 6/10 (NRS), maximum pain at 
6–10/10 (NRS). The pain reduction achieved 
individually following ambroxol cream was 
2–8 points (NRS) within 5–30 min and lasted 
for 3–8 h. Pain attacks were reduced in all five 
patients presenting with this problem. Four 
patients with no improvement after lidocaine 
5 % and one patient with no response to cap-
saicin 8 % nevertheless experienced a pain 
reduction with topical ambroxol. No patient 
reported any side effects or skin changes dur-
ing a treatment that has since been contin-
ued for up to 4 years.
Conclusion. Ambroxol acts as a strong lo-
cal anaesthetic and preferentially inhibits the 
nociceptively relevant sodium channel sub-
type Nav 1.8. For the first time, we report be-
low on a relevant pain relief following topical 
ambroxol 20 % cream in patients with neuro-
pathic pain. In view of the positive side effect 
profile, the clinical benefit in patients with 
pain should be investigated further.
Keywords
Ambroxol · Neuropathic pain · Topical 
therapy · Nav 1.8 · Local anaesthetic
Topisches Ambroxol zur Behandlung neuropathischer Schmerzen. Eine erste, klinische Beobachtung
Zusammenfassung
Hintergrund. Neuropathische Schmerzen 
sind schwer behandelbar, die vorhandenen 
Therapien oft nicht ausreichend. Das Sekre-
tolytikum Ambroxol hat auch stark lokalanäs-
thetische Eigenschaften und hemmt Natri-
umkanäle ca. 40 mal potenter als Lidocain. Es 
blockiert bevorzugt den Kanalsubtyp Nav 1.8, 
der besonders in nozizeptiven C-Fasern expri-
miert wird. Bei geringer Toxizität erschien ein 
Behandlungsversuch mit topischen Ambro-
xol berechtigt bei unzureichend behandel-
baren, neuropathischen Schmerzen.
Material und Methode. Retrospektiv wer-
den exemplarisch 7 Krankheitsverläufe von 
Patienten mit schweren, neuropathischen-
Schmerzen dargestellt, bei denen viele Be-
handlungsversuche mit zugelassenen Sub-
stanzen erfolglos odernicht möglich waren. 
Diese waren in einem umschriebenen Are-
al topisch mit einer Ambroxol 20 %-Cremebe-
handelt worden.
Ergebnisse. Schmerzursachen waren: Post-
zosterneuralgie (2 ×), Mononeuropathia mul-
tiplex, Deafferenzierungsschmerz, Phantom-
schmerz, postoperative Neuralgie und un-
klare Fußneuropathie. Diedurchschnittlichen 
Schmerzstärken lagen zwischen 4–6/10  
(NRS), maximal bei 6–10/10. DieSchmerz-
reduktionen unter Ambroxol betrugen 2–8 
Punkte (NRS) binnen 15–30 min und hielten 
3–8 h an.Schmerzattacken reduzierten sich 
bei allen 5 Betroffenen. 4 Patienten ohne vor-
herige Besserung auf Lidocain 5 % und 1 Pa-
tient ohne Linderung auf Capsaicin 8 % pro-
fitierten dennoch von topischem Ambro-
xol. Kein Patient berichtete Nebenwirkungen 
oder Hautveränderungen, die längste Be-
handlung überblickt mittlerweile 4 Jahre.
Schlussfolgerung. Ambroxol wirkt als 
starkes Lokalanästhetikum und blockiert be-
vorzugt den nozizeptiv relevanten Kanalsub-
typ Nav 1.8. Wir berichten hier erstmals über 
eine relevante Schmerzlinderung durch to-
pisches Ambroxol 20 % bei Patienten mit neu-
ropathischem Schmerz. Angesichts des gün-
stigen Nebenwirkungsprofils sollte der kli-
nische Nutzen für Schmerzpatienten drin-
gend weiter untersucht werden.
Schlüsselwörter
Ambroxol · Neuropathischer Schmerz · 
Topische Therapie · Nav 1.8 · Lokalanästhesie
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lodynia (without pinprick hyperalgesia). 
Following many unsuccessful treatments 
(includes opiates and anticonvulsants), 
the topical ambroxol 20 % cream managed 
to produce a relevant effect: the extreme 
cold sensation in the phantom regressed 
distinctly after approximately 15 min for 
several hours, and the phantom limb felt 
warmer. This effect has persisted un-
changed for over 11 months now. No skin 
changes of any kind or any other side ef-
fects occurred on the stump, and the case 
report is documented on video.
Case report 3 (Neuropathic pain 
after total knee replacement)
This 58-year-old female patient received a 
total knee replacement in November 2010, 
after which considerable pains persisted. 
Clinical examination revealed an exten-
sive dynamic allodynia and pinprick hy-
peralgesia medially as a sign of central 
sensitization. There were no signs of in-
flammation or movement-related pain. 
The existing treatment with buprenor-
phine 10 ug/h had been replaced by tapen-
tadol because of the neuropathic nature 
of the pain, but this had proved no bet-
ter in relieving the pain. After capsaicin 
8 % plasters, the pain became slightly less 
frequent and of shorter duration. Since 
the knee pain was still persisting substan-
tially by April 2014 and lidocaine plasters 
had also not been very helpful, topical am-
broxol 20 % was used during the consulta-
tion. After just 15 min the patient report-
ed clear pain relief: the burning and stab-
bing had subsided distinctly, while a ‘rag-
ing feeling’ in the knee disappeared almost 
completely. After applying the cream re-
peatedly over the next few months, she 
observed a reduction in pain for 4–6 h 
after approximately 30 min in each case, 
from an average of NRS 8/10 before treat-
ment to 4/10 NRS (. Fig. 2), and occasion-
ally even down to NRS 1/10. With the most 
extreme pain (NRS 10/10), she found that 
the pain no longer returned to this level 
after the treatment. She has been apply-
ing topical ambroxol 20 % cream regular-
ly for 11 months now, without any side ef-
fects or skin reactions. The case report is 
documented on video.
Case report 4 (Deafferentation pain)
The 38-year-old patient presented in 
April 2014 with deafferentation pains in 
the left arm after a plexus lesion (motor-
cycle accident in 1997), with subsequent 
mechanical allodynia in hand and fore-
arm. A nerve graft proved unsuccess-
ful, as did ketamine, gabapentin and a li-
docaine infusion. Mirror therapy ended 
with a worsening of the pain for sever-
al days, while amitriptyline produced ex-
cessive sedation. Although cannabis (in 
connection with a clinical study) man-
aged to reduce the pain by 60 %, it also re-
sulted in substantial mental impairment. 
His medication now consisted of prega-
balin 2 × 300 mg and duloxetine 60 mg. 
Slight innervation of the biceps mus-
cle and shoulder elevation were possible, 
as was mental motor imagery to modu-
late the phantom pain. The patient expe-
rienced three types of pain in the arm: a 
‘burning pain’ (started by the application 
of cold to the hand), a ‘crushing underly-
ing pain’ (with no trigger) and ‘shooting 
tingling pains’. The pain intensity ranged 
from NRS 4–8/10, and there was no dy-
namic allodynia at the elbow. Sensations 
could be triggered in the phantom arm by 
cold stimuli to the subclavicular area and, 
as referred pains, from trigger points from 
the subclavian and pectoral muscles. Li-
docaine plasters merely changed the na-
ture of the pain, while trigger point treat-
ments and tapentadol were not tolerated. 
A test was therefore initiated with topi-
cal ambroxol 20 % cream over the pecto-
ral muscle, which successfully relieved the 
shooting and tingling pains in most cas-
es from NRS 8/10 to 4/10. Since then the 
effect has been described as starting after 
approximately 15 min and persisting for 
4–6 h, which proved crucially important 
particularly in falling asleep. However, 
the ‘deep underlying pain’ remained unaf-
fected. The patient was especially happy 
about the spontaneous cessation, without 
triggers, of repeatedly occurring spasms 
and cramps, which enabled him to con-
tinue everyday tasks at these times. The 
patient’s descriptions are documented on 
video.
Case report 5 (Thoracic 
postherpetic neuralgia)
This 55-year-old patient presented in Au-
gust 2008 with a postherpetic neuralgia 
on the right side of the chest (intensity 
5/10) that had been present for 2 months. 
Step I and Step II analgesics only reduced 
the pain slightly, while lidocaine plasters 
proved very effective. Clinical examina-
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allodynia at T6-8 on the right. He was ini-
tially treated successfully with increasing 
doses of gabapentin, and his night-time 
sleep improved with amitriptyline drops. 
Since other sedating substances were not 
possible and capsaicin 8 % remained un-
successful, the use of topical ambroxol 
20 % cream was tried in April 2012. Al-
though this was unable to control the pain 
adequately on its own, it did manage to re-
duce the pain, starting after 30 min, from 
NRS 6/10 to 4/10 (. Fig. 3) for a period of 
4–6 h. The patient applies the cream for 
pain attacks and for those areas that are 
not well covered by the lidocaine plasters, 
which he continues to use. No adverse ef-
fects or skin reactions have been reported 
after what is now more than 3 years of use.
Case report 6 (mononeuropathy 
multiplex)
This patient presented in November 2013 
with neuropathic pain in the arch of the 
left foot and multiplex neuritis as a re-
sult of vasculitis. He described two types 
of pain: a permanent underlying pain that 
interfered considerably with this every- 
day activities, and he also reported at- 
tacks of fierce pain, particularly in the 
evenings while watching television and at 
night, with an intensity up to NRS 8/10. 
Meanwhile he has been receiving treat-
ment for depression with duloxetine 
60 mg and lithium. Lidocaine plasters, 
peripheral analgesics and low-dose tili-
dine had already been tried without suc-
cess. His night-time sleep was now deep-
ened with amitriptyline drops, while the 
dosage of the tilidine was cautiously in-
creased. Since the central nervous tolera-
bility threshold had already been reached 
at the second visit in December 2013, a test 
was arranged with topical ambroxol. This 
proved highly effective: the patient report-
ed a reduction in his evening, neuropath-
ic pain from NRS 6/10 to 2/10, starting af- 
ter 15 min and lasting for over 6 h. He was 
able to watch television without interrup-
tion, while his night-time sleep (after ap-
plying the cream immediately before-
hand) was usually good. The zolpidem 
that he had been using for a long time was 
now unnecessary. When he was woken by 
pain, further application of the cream pro-
duced rapid pain relief. After 4 months of 
use, the permanent underlying pain dur-
ing the day disappeared almost complete-
ly. A notable finding was the absence be-
fore treatment in this patient of any kind 
of allodynia or hyperalgesia in response to 
dynamic or pinprick stimuli or to cold or 
draughts of air. Having applied the cream 
for a period of 17 months now, the patient 
continues to use this treatment (. Fig. 4) 
and has not reported any form of skin re- 
actions or side effects to date. The patient’s 
statements have been documented repeat- 
edly on video.
Case report 7 (Trigeminal 
postherpetic neuralgia)
After contracting a zoster infection of the 
V2 branch on the left in June 2014, this 
91-year-old female complained of facial 
pain up to the intensity of NRS 8/10. Af-
fective pain perception was considerable, 
and her night-time sleep was greatly dis-
turbed. Diclofenac, tramadol and met-
amizole were not sufficient. Her night-
time sleep was initially improved with a 
few amitriptyline drops, but an increase 
in the tramadol dosage failed due to con-
stipation and sedation. Lidocaine plasters 
were effective, but had to be discontin-
ued due to skin reactions. Since the dos-
age of gabapentin (100 mg) could only be 
increased to a limited extent and capsaicin 
8 % did not appear to be indicated in this 
elderly woman, ambroxol 20 % cream was 
attempted. She has now been using this for 
11 months and describes the effect as clear-
ly pain-relieving, and felt that her cheek 
became ‘calmer’ approximately 15 min af-
ter each application. If she awoke at night, 
she was able to fall asleep again without 
pain sometime after a further application. 
This use has also been continued now for 
10 months without any adverse effects and 
is documented on video.
Discussion
In this case series we describe, for the first 
time, patients whose neuropathic pain 
was relieved by the topical application 
of ambroxol. The pain reduction was be-
tween 33 and 100 % (or between 2 and 8 
NRS points; . Table 1) and can therefore 
be considered as clinically relevant [12]. 
The findings can be explained by the so-
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Pharmacology, sodium channels 
and analgesic effect
Ambroxol is structurally similar to known 
local anaesthetics (‘Löfgren structure’) 
and, like these, binds to a specific bind-
ing site of the neuronal sodium channel 
[27]. It likewise blocks the sodium influx 
at voltage-dependent sodium channels, 
which leads to a reduction in the action 
potential frequency and thus in intraneu-
ral signal transduction.
However, certain properties suggest 
that ambroxol is of particular interest for 
the treatment of neuropathic pain. Firstly, 
it is very potent: ambroxol inhibits neuro-
nal sodium channels at an approximate-
ly 40-fold lower concentration than lido-
caine [47], thereby alleviating neuropathic 
pain after local [29] and systemic applica-
tion [13]. Secondly, in animal studies (and 
in contrast with lidocaine), it blocks noci-
ceptor-specific sodium channels more po-
tently than other neuronal sodium chan-
nels [47]. This may explain why four of 
our patients in whom lidocaine had previ-
ously proved ineffective nevertheless prof-
ited from ambroxol, which also produced 
a very powerful effect in animal models of 
neuropathic pain after systemic adminis-
tration [14, 16], at least as strong as that 
of gabapentin and at dosages that can cer-
tainly be employed in clinical practice [14, 
49].
Voltage-gated sodium channels (Nav; v 
= voltage gated) in nerve cell membranes 
play an important role in signal transduc-
tion, including in nociceptive neurons. 
Nine subtypes are described (Nav 1.1–1.9) 
[8]. The neuronally expressed channels 
Nav 1.1, 1.2, 1.3, 1.6 and 1.7 are inhibited 
with high affinity by tetrodotoxin (TTX), 
the toxin of the pufferfish. The subtypes 
expressed predominantly in nociceptive 
neurons, that is Nav 1.8 and 1.9, are TTX-
resistant [37]. Ambroxol blocks TTX-re-
sistant sodium channels to a much greater 
degree than TTX-sensitive channels. The 
TTX-r-subtype Nav 1.8, which is preferen-
tially blocked by ambroxol, is expressed 
particularly in spinal ganglion cells [2]. 
In nerve injuries, it appears to play an im-
portant role in the sensitization of noci-
ceptors and thus contribute to the devel-
opment and maintenance of neuropath-
ic pain [3, 21, 26, 36]. It is thought to be 
particularly important in pain caused by 
cold [52]. A connection with the observa-
tion of ‘warming of the ice-cold phantom 
leg’ by the application of ambroxol to the 
stump of patient 2 remains to be seen. Nav 
1.8 blockade also proved to be clearly an-
algesic in animal studies [11, 20]. So the 
improvements in our patients are credible 
not just on the basis of its continued use 
for prolonged periods.
Nav 1.8 expression
After nerve injuries, the redistribution or 
expression of sodium channels can occur 
in primary nociceptive neurons, with a re-
sulting low threshold for triggering pain 
or for the hyperexcitability of DRG neu-
rons. The subtype Nav 1.8 is selectively ex-
pressed in nociceptive, sensory neurons 
[2, 6, 35, 52], but to a greater extent in 
nerve pain models [15, 44] and also in pa-
tients with neuropathic pain [24, 50]. This 
is also thought to be important in both an-
imals and humans for the spontaneous ac-
tivity in neuromas [5, 24, 36], which might 
have played a role in our amputated pa-
tients (case report 2). This may also ex-
plain the reduction in attacks of pain in all 
our five patients concerned. Increased Nav 
1.8 expression also occurs in diabetic poly-
neuropathy [30], small-fibre neuropathy 
[19], radiculopathies [17, 44], trigeminal 
neuralgia [41], but also in arthritis [39, 43] 
and bone metastases [33]. Nav 1.8 block-
ade (e.g. produced by ambroxol) is also ul-
timately considered as an option for the 
treatment of neuropathic pain, because 
investigations with Nav 1.8-free mice and 
Nav 1.8-blocking substances have shown 
lower mechanical, thermal and visceral 
hyperexcitability in the animal model [1, 
4, 11, 18, 20, 21, 45, 46].
Clinical significance, 
safety and dosage
Although ambroxol binds to the same lo-
cal anaesthetic binding sites as lidocaine 
and amitriptyline, none of the substanc-
es used to date for neuropathic pain (in-
cludes local anaesthetics, antidepressants 
and anticonvulsants) have shown any rel-
evant selectivity for the Nav 1.8 channel 
comparable with that of ambroxol [27, 
48]. The sodium-channel blockers used 
for treating pain, that is amitriptyline 
and carbamazepine, also do not block the 
channel types selectively [7, 42]. The se-
lective blockade by ambroxol of the Nav 
1.8 channel type, which is not represent-
ed in the cardiac or central nervous sys-
tems, may therefore prove clinically ben-
eficial. At least we did not receive any re-
ports of corresponding adverse effects in 
any of our patients, including in those 
who have been using the substance top-
ically for a long time now. This is also not 
surprising in that, despite the potent so-
dium channel blockade, the tolerability of 
ambroxol itself is very good after system-
ic administration: even intravenous dos-
es as high as 1 g (for promoting prenatal 
lung maturation and the treatment of at-
electasis) are well tolerated [51, 53]. There 
are even isolated reports of doses of up to 
3 g a day being administered for up to 53 
days [9, 28, 38] and the oral administra-
tion of 1.3 g ambroxol a day for 33 days 
[22]. After animal studies showed that 
high-dose ambroxol was clearly analgesic 
and well tolerated, Gaida et al. [14] pre-
sumed that these high dosages were prob-
ably necessary to produce analgesia. But 
with our topical treatments, we were able 
to show that even low-dose peripheral ap-
plications can have a clearly analgesic ef-
fect. Furthermore, no skin changes were 
observed by us, even though correspond-
ing case reports exist [31].
In view of this interesting therapeu-
tic approach, a number of other Nav 
1.8-blocking substances are currently be-
ing developed. However, its highly potent 
blockade, good bioavailability and very 
few side effects make ambroxol a partic-
ularly interesting substance, and one that 
should prove at least as useful as other so-
dium channel blockers for the treatment 
of chronic pain [27]. The safety and tol-
erability of systemically administered 
ambroxol—even at dosages on the gram 
scale—have been demonstrated over de-
cades of clinical experience.
Ambroxol and allodynia
Apart from case report 6, all patients suf-
fered from hypersensibility to mechanical 
stimuli which regressed in each case af-
ter topical ambroxol. Is this anti-allodynic, 
analgesic effect really conceivable?
S94 | Der Schmerz Suppl 3 · 2015
Original Article
Allodynia and hyperalgesia are con-
sidered to be neuroplastic phenomena of 
the spinal sensory system [25]. The Nav 
1.8 channel is detected mainly in C- or 
A-delta fibres and neurons of the poste-
rior horn [2, 6, 35, 52], although it is al-
so expressed in A-beta fibres [1, 4, 26, 34, 
40]. But since chronic inflammation shifts 
the excitability of Nav 1.8 toward hyperpo-
larization this contributes to the allodyn-
ia, which means that ambroxol blockade 
would therefore be particularly pain-re-
lieving. In animal studies, ambroxol also 
suppressed allodynia to differing degrees 
after systemic administration: heat hy-
peralgesia by 100 %, cold hyperalgesia and 
mechanical allodynia by approximate-
ly 75 % [14]. The intrathecal administra-
tion also showed an anti-allodynic effect 
in animal experiments [32]. The obser-
vation that ambroxol also managed to re-
duce mechanical allodynia in rats with ex-
perimental induced inflammation by ap-
proximately 2/3 [4] suggests that the anti-
allodynic, analgesic effect is not necessar-
ily limited just to neuropathic pain. In the 
patients described in this article, at least, 
the allodynia in response to mechanical 
stimuli was alleviated in all cases by topi-
cal ambroxol, which can now be explained 
by the rationale described above.
Onset and duration of effect
The onset of Nav 1.8 blockade in vitro by 
ambroxol starts within a few seconds and 
is concentration-dependent and fully re-
versible [27]. In paraplegic rats hypersen-
sitivity to static mechanical stimuli was re-
duced after approximately 30 min for ap-
proximately 3 h [16]. Both findings corre-
late closely with the statements of our pa-
tients (. Fig. 2), according to which the 
effect started between 15 and 30 min after 
application. In case report 1, the effect was 
frequently even said to appear ‘immedi-
ately’ and persisted for well over 6 h in this 
patient. When applied repeatedly, topical 
lidocaine 5 % often shows an increasing 
effect over time, both clinically and ac-
cording to the literature [29]. A compa-
rable result was also reported by our pa-
tient 6, who felt that his underlying pain 
had almost disappeared after 4 months of 
use. The significance of these observations 
needs to be explored in greater depth.
Limitations
This case series describes (in an open-la-
bel, uncontrolled design) examples of the 
successful outcome of a topical treatment 
with ambroxol 20 % in patients with neu-
ropathic pain. It is therefore still subject to 
numerous possible sources of error, from 
placebo effects to temporary therapeutic 
successes with no long-term significance, 
even though some of the treatments are 
documented here for several years. Al-
though these were pooled, by way of ex-
ample, for many other patients, they were 
compiled only retrospectively and, in this 
article, only for neuropathic pain. Since 
amount and depth of ambroxol’s skin pen-
etration from the cream are not known, 
it cannot be stated conclusively whether 
the analgesic effects are based solely on 
its local action or on partial systemic ef-
fects. However, the latter would proba-
bly already have come to light clinically 
in view of the widespread use of ambrox-
ol for respiratory disorders. An improve-
ment to this initial formulation would al-
so doubtless be possible. Therefore the 
observations do not yet allow any gener-
al conclusions to be drawn concerning the 
degree of efficacy in humans. Systematic 
and controlled studies on these questions 
are needed.
Conclusion for practice
The expectorant ambroxol also acts as a 
very potent local anaesthetic. It signifi-
cantly and preferentially blocks the noci-
ceptively relevant sodium channel sub-
type Nav 1.8 to a greater extent than all 
other local anaesthetics. Increased Nav 
1.8 expression is detected in neuropathic 
pain and is almost exclusively limited to 
sensory pain fibres. Its blockade is there-
fore considered to be a useful, simple 
concept for pain management with few 
side effects. In the case reports present-
ed in this article, this concept was suc-
cessfully implemented, for the first time, 
in the form of topical ambroxol 20 % 
cream in patients with severe neuro-
pathic pain. This preparation has mean-
while been used for over 4 years without 
any undesirable effects. Since the devel-
opment of new substances for the treat-
ment of neuropathic pain is very ardu-
ous and time-consuming, we believe 
that there is an urgent need for further 
extensive research on the clinical use of 
well-known traditionally used substanc-
es with clear anti-nociceptive effects and 
positive side effect profiles, for exam-
ple ambroxol. In view of the considerable 
distress caused by failed treatments the 
use of such substances should also be 
considered in connection with individual 
therapeutic trials.
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